Dacomitinib

Definition

A highly selective, orally bioavailable small-molecule inhibitor of the HER family of tyrosine kinases with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human Her-1, Her-2, and Her-4, resulting in the proliferation inhibition and apoptosis of tumor cells that overexpress these receptors.

NCIT:C53398 · NCI Thesaurus OBO Edition · CC BY 4.0

Also known as (2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide, DACOMITINIB, EGFR Inhibitor PF-00299804, PF 00299804, PF-00299804, PF-00299804-03, PF-299804, PF00299804, Vizimpro — per NCIT

Also identified as

ATC L01EB07 per RXNORM
NCIT NCIT:C53398 per NCIT
SCTID 781492009 per RXNORM
SCTID 781495006 per RXNORM
UNII 5092U85G58 per RXNORM

Indications

Disease	Relation	Source
Non-small cell lung carcinoma	may treat	MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ	Side effect / interaction	Source
Lungs	may treat a disease of this organ	DERIVED · CC BY 4.0

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.